Current challenges in applying gene-driven therapies in clinical lung cancer practice

doi:10.5306/wjco.v12.i8.656

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3465)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

220

WORD

HTML

1740

Figures (1-2)

331

Tables (1-2)

314

Sum=2687

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

300

Download

478

Sum=778

Aug 24, 2021 (publication date) through Jan 23, 2025

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Aug 24, 2021; 12(8): 656-663
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.656

Full Size Figure Download Figure

Figure 2 Presenting the history of the European Medicines Agency approvals and reimbursement situation in Finland (40% reimbursement and 100% reimbursement), concerning gene-driven therapies for lung cancer. NTRK: Neurotrophic receptor tyrosine kinase; PET: Positron emission tomography; CT: Computed tomography; EMA: European Medicines Agency; ALK: Anaplastic lymphoma kinase; EGFR: Epidermal growth factor receptor.

Citation: Saarenheimo J, Andersen H, Eigeliene N, Jekunen AP. Current challenges in applying gene-driven therapies in clinical lung cancer practice. World J Clin Oncol 2021; 12(8): 656-663
URL: https://www.wjgnet.com/2218-4333/full/v12/i8/656.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i8.656